Soy and soy isoflavones in prostate cancer: A systematic review and meta-analysis of randomized controlled trials

BJU International

Volumn 113, Issue 5 B, 2014, Pages

  Van Die, M Diana ^a   Bone, Kerry M ^b,c   Williams, Scott G ^a,d   Pirotta, Marie V ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Integria (MediHerb)   (Australia)

^c NEW YORK CHIROPRACTIC COLLEGE   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Glycine max; Isoflavones; Phytoestrogens; Prostate cancer; Prostatic hyperplasia; Soy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANDROSTANOLONE; BILIRUBIN; CALCIUM; ESTRADIOL; ISOFLAVONE DERIVATIVE; PHOSPHORUS; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL LIPASE; PHYTOESTROGEN; SOYBEAN PROTEIN;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOATING; CALCIUM BLOOD LEVEL; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; DIARRHEA; DIET SUPPLEMENTATION; DRUG SAFETY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; ILEUS; ILIAC ARTERY OBSTRUCTION; LOOSE FECES; LOSS OF APPETITE; META ANALYSIS; PATIENT SAFETY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SOYBEAN; SURVIVAL RATE; SYSTEMATIC REVIEW; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPREGULATION; MALE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REVIEW; SOY;

GLYCINE MAX; ISOFLAVONES; PHYTOESTROGENS; PROSTATE CANCER; PROSTATIC HYPERPLASIA; SOY;

HUMANS; ISOFLAVONES; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOYBEAN PROTEINS;

EID: 84902332134     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12435     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917
3. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 1991; 30: 133-40
4. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63: 963-6
5. Kolonel LN. Variability in diet and its relation to risk in ethnic and migrant groups. Basic Life Sci 1988; 43: 129-35
6. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis.Am J Clin Nutr 2009; 89: 1155-63
7. Messina M, Kucuk O, Lampe JW. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 2006; 89: 1121-34 (Pubitemid 44972063)
8. Steiner C, Arnould S, Scalbert A, Manach C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 2008; 99 E (Suppl. 1): ES78-108
9. Wuttke W, Jarry H, Seidlova-Wuttke D. Plant-derived alternative treatments for the aging male: facts and myths. Aging Male 2010; 13: 75-81
10. Wuttke W, Jarry H, Seidlova-Wuttke D. Isoflavones-safe food additives or dangerous drugs? Ageing Res Rev 2007; 6: 150-88 (Pubitemid 47017808)
11. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 2006; 55: 1-12 (Pubitemid 44477039)
12. Zamora-Ros R, Knaze V, Lujan-Barroso L et al. Dietary intakes and food sources of phytoestrogens in the European Prospective Investigation into Cancer and Nutrition (EPIC) 24-hour dietary recall cohort. Eur J Clin Nutr 2012; 66: 932-41
13. Mulligan AA, Welch AA, McTaggart AA, Bhaniani A, Bingham SA. Intakes and sources of soya foods and isoflavones in a UK population cohort study (EPIC-Norfolk). Eur J Clin Nutr 2007; 61: 248-54
14. Kuhnle GGC, Dell'Aquila C, Runswick SA, Bingham SA. Variability of phytoestrogen content in foods from different sources. Food Chem 2009; 113: 1184-7
15. King R, Bignell C. Concentrations of isoflavone phytoestrogens and their glucosides in Australian soya beans and soya foods. Aust J Nutr Diet 2000; 57: 70-8
16. Bhagwat S, Haytowitz DB, Holden JM. USDA database for the isoflavone content of selected foods release 2.0. Nutrient Data Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service U.S. Department of Agriculture, September 2008
17. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132: 3577-84 (Pubitemid 35435031)
18. Lampe JW, Karr SC, Hutchins AM, Slavin JL. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 1998; 217: 335-9
19. Akaza H, Miyanaga N, Takashima N et al. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 2004; 34: 86-9 (Pubitemid 43115325)
20. Yan L, Spitznagel EL. Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 2005; 117: 667-9 (Pubitemid 41504557)
21. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008; 269: 226-42
22. Vij U, Kumar A. Phyto-oestrogens and prostatic growth. Natl Med J India 2004; 17: 22-6 (Pubitemid 38461227)
23. Horie S. Chemoprevention of prostate cancer: soy isoflavones and curcumin. Korean J Urol 2012; 53: 665-72
24. Hamilton-Reeves JM, Rebello SA, Thomas W, Slaton JW, Kurzer MS. Soy protein isolate increases urinary estrogens and the ratio of 2:16alphahydroxyestrone in men at high risk of prostate cancer. J Nutr 2007; 137: 2258-63 (Pubitemid 47529587)
25. Hamilton-Reeves JM, Rebello SA, Thomas W, Slaton JW, Kurzer MS. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer. J Nutr 2007; 137: 1769-75 (Pubitemid 47037705)
26. Lazarevic B, Boezelijn G, Diep LM et al. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind phase 2 clinical trial. Nutr Cancer 2011; 63: 889-98
27. DeVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer 2010; 62: 1036-43
28. Kumar NB, Cantor A, Allen K et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004; 59: 141-7 (Pubitemid 38481225)
29. Kumar NB, Kang L, Pow-Sang J et al. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol 2010; 8: 3-13
30. Miyanaga N, Akaza H, Hinotsu S et al. Prostate Cancer Chemoprevention Study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci 2012; 103: 125-30
31. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (version 5.0.1). 2008
32. Kumar NB, Krischer JP, Allen K et al. A phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 2007; 59: 163-8 (Pubitemid 350230733)
33. Kumar NB, Krischer JP, Allen K et al. Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer 2007; 59: 169-75 (Pubitemid 350230734)
34. Hamilton-Reeves JM, Rebello SA, Thomas W, Kurzer MS, Slaton JW. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer 2008; 60: 7-13 (Pubitemid 351192916)
35. Dalais FS, Meliala A, Wattanapenpaiboon N et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004; 64: 510-5 (Pubitemid 39200748)
36. Kranse R, Dagnelie PC, van Kemenade MC et al. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer 2005; 113: 835-40 (Pubitemid 40101267)
37. Hamilton-Reeves JM, Vazquez G, Duval SJ, Phipps WR, Kurzer MS, Messina MJ. Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: results of a meta-analysis. Fertil Steril 2010; 94: 997-1007
38. Tanaka M, Fujimoto K, Chihara Y et al. Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers. Prostate Cancer Prostatic Dis 2009; 12: 247-52
39. Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S. Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. J Clin Oncol 2008; 26: 5923-9
40. Ozasa K, Nakao M, Watanabe Y et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 2004; 95: 65-71 (Pubitemid 38208409)
41. Lampe JW. Emerging research on equol and cancer. J Nutr 2010; 140: 1369S-72S
42. Hsu A, Bray TM, Helferich WG, Doerge DR, Ho E. Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med (Maywood) 2010; 235: 90-7
43. Xu L, Ding Y, Catalona WJ et al. MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst 2009; 101: 1141-55
44. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7 (Pubitemid 29211767)